Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 15/3/2021
SIETES contiene 93212 citas

 
 
<< anterior 21 a 40 de 5109 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
Hababi S, Heinrich A, Omer SB. No-fault compensation for vaccine injury — The other side of equitable access to covid-19 vaccines. N Engl J Med 2020;383:3 de diciembre. [Ref.ID 103803]
22.Enlace a cita originalTiene citas relacionadas Cita con resumen
Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Chappel JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD, Neuzil KM, Bennett H, Leav B, Makowski M, Albert J, Cross K, Edara V-V, Floyd K, Suthar MS, Buchanan W, Luke CJ, Ledgerwood JE, Mascola JR, Graham BS, Beigel JH, for the mRNA-1273 Study Group. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med 2020:3 de diciembre. [Ref.ID 103800]
23.Enlace a cita original Cita con resumen
Mitjà O, Corbacho-Monné M, Ubals M, Alemany A, Suñer C, Tebé C, Tobias A, Peñafiel J, Ballana E, Pérez CA, Admella P, Riera-Martí N, Laporte P, Mitjà J, Clua M, Bertran L, Sarquella M, Gavilán S, Ara J, Argimon JM, Cuatrecasas G, Cañadas P, Elizalde-Torrent A, Fabregat R, Farré M, Forcada A, Flores-Mateo G, López C, Muntada E, Nadal N, Narejos S, Nieto A, Prat N, Puig J, Quiñones C, Ramírez-Viaplana F, Reyes-Urueña J, Riveira-Muñoz E, Ruiz L, Sanz S, Sentís A, Sierra A, Velasco C, Vivanco-Hidalgo RM, Zamora J, Casabona J, Vall-Mayans M, González-Beiras C, Clotet B, for the BCN-PEP CoV2 Research Group. A cluster-randomized trial of hydroxychloroquine for prevention of covid-19. N Engl J Med 2020;384:24 de noviembre. [Ref.ID 103796]
24.Enlace a cita originalTiene citas relacionadas Cita con resumen
Almario CV, Chey WD, Spiegel BMR. Increased risk of COVID-19 among users of proton-pump inhibitors. The American Journal of Gastroenterology 2020;115:octubre. [Ref.ID 103795]
25. Cita con resumen
Zhang X-Y, Wu H-B, Ling Y, Qian Z-P, Chen L. Analysis of the effect of proton pump inhibitors on the course of common COVID-19. medRxiv 2020:13 de junio. [Ref.ID 103794]
26. Cita con resumen
Jimenez L, Campos Codo A, de Souza Sampaio V, Oliveira AER, Kobo Ferreira LK, Gastao Davanzo G, et al.. The influence of pH on SARS-CoV-2 infection and COVID-19 severity. medRxiv 2020:. [Ref.ID 103792]
27. Cita con resumen
Vila-Corcoles A, Satue-Gracia E, Ochoa-Gondar O, Torrente-Fraga C, Gomez-Bertomeu F, Vila-Rovira A, Hospital-Guardiola I, de Diego-Cabanes C, Bejarano-Romero F, Rovira-Veciana D, Basora-Gallisa J. Use of distinct anti-hypertensive drugs and risk for COVID-19 among hypertensive people: A population-based cohort study in Southern Catalonia, Spain. The Journal of Clinical Hypertension 2020;22:agosto. [Ref.ID 103791]
28.Enlace a cita original Cita con resumen
Li G-F, An X-X, Yu Y, Jiao L-R, Canarutto D, Yu G, Wang G, Wu D-N, Xiao Y. Do proton pump inhibitors influence SARS-CoV- 2 related outcomes? A meta-analysis. Gut 2020:10 de noviembre. [Ref.ID 103790]
29.Enlace a cita original Cita con resumen
Nguyen D-D, Marchese M, Cone EB, Paciotti M, Basaria S, Bhojani N, Trinh Q-D. Investigation of suicidality and psychological adverse events in patients treated with finasteride. JAMA Dermatol 2020:11 de noviembre. [Ref.ID 103784]
30.Enlace a cita original Cita con resumen
Dal-Ré R, Caplan AL, Gluud C, Porcher R. Ethical and scientific considerations regarding the early approval and deployment of a COVID-19 vaccine. Ann Intern Med 2020:20 de noviembre. [Ref.ID 103783]
31. Cita con resumen
Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, Gabbay FJ, Davies DE, Holgate ST, Ho L-P, Clark T, Djukanovic R, Wilkinson TMA, on behalf of the Inhaled Interferon Beta COVID-19 Study Group. . The Lancet Respiratory Medicine 0:1. [Ref.ID 103778]
32.Enlace a cita originalTiene citas relacionadas Cita con resumen
Pathak EB. Convalescent plasma is ineffective for covid-19. BMJ 2020;371:22 de octubre. [Ref.ID 103776]
33. Cita con resumen
34. Cita con resumen
de Vries RD, Schmitz KS, Bovier FT, Noack D, Haagmans BL, Biswas S, Rockx B, Gellman SH, Alabi CA, de Swart RL, Moscona A, Porotto M. Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets. biorxiv.com 2020:5 de noviembre. [Ref.ID 103772]
35.Tiene citas relacionadas Cita con resumen
Parsons L. Russia claims its COVID-19 vaccine is over 90% effective. PMLiVE 2020:1. [Ref.ID 103771]
36.Enlace a cita originalTiene citas relacionadas Cita con resumen
Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P, on behalf of the PLACID Trial Collaborators. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ 2020;371:22 de octubre. [Ref.ID 103770]
37. Cita con resumen
Gelles D. La difícil tarea de transportar una vacuna que debe estar a 80 grados Celsius bajo cero. N Y Times (Print) 2020:21 de septiembre. [Ref.ID 103767]
38. Cita con resumen
Doshi P. Covid-19 vaccine trial protocols released. BMJ 2020:m4058. [Ref.ID 103766]
39.Enlace a cita original Cita con resumen
Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. The Lancet Infectious Diseases 2020:27 de octubre. [Ref.ID 103764]
40. Cita con resumen
Krause PR, Fleming TR, Ellenberg SS, Henao-Restrepo AM, on behalf of the WHO Ad Hoc Clinical Trial Expert Group. Maintaining confidentiality of emerging results in COVID-19 vaccine trials is essential. Lancet 2020;396:21 de noviembre. [Ref.ID 103763]
Seleccionar todas
 
<< anterior 21 a 40 de 5109 siguiente >>